SALT LAKE CITY, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that
it has engaged Donohoe Advisory Associates, LLC (“Donohoe Advisory”) in connection with its efforts to seek a
listing for its common shares on a national securities exchange.
Donohoe Advisory was founded by Dave Donohoe in 2004, and since that time the firm has successfully represented hundreds of
companies in a wide range of listing proceedings and engagements at both Nasdaq and the NYSE. Each professional member of Donohoe
Advisory’s team previously worked for either The Nasdaq Stock Market (“Nasdaq”) or the New York Stock Exchange (the “NYSE”). Prior to forming Donohoe Advisory, Dave Donohoe
spent 9+ years with Nasdaq, where he ultimately served as Chief Counsel in the Listing Qualifications Department.
Bradley Robinson, CEO, Predictive Technology Group, Inc. states, “At this juncture in PRED’s corporate growth, PRED believes it
is well positioned to pursue a listing on a recognized exchange. Hiring Donohoe Advisory will help to further this
effort.”
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (OTCPINK: PRED), a Salt Lake City, UT, based Life-Sciences
Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics,
and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary
companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue
Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated,
registered laboratories. PRED’s subsidiaries use genetic and other information as cornerstones in the development of new
diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more
effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com.
For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.
Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these
statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA
approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and
pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of
additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the
Company may identify from time to time in the future.
Contact: Rich Kaiser
Investor Relations
757-306-6090
